Kura Oncology
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kura Oncology and other ETFs, options, and stocks.About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
KURA Key Statistics
Stock Snapshot
The current Kura Oncology(KURA) stock price is $10.75, with a market capitalization of 943.7M. The stock trades at a price-to-earnings (P/E) ratio of -4.52.
On 2025-11-17, Kura Oncology(KURA) stock traded between a low of $10.75 and a high of $11.66. Shares are currently priced at $10.75, which is 0.0% above the low and -7.8% below the high.
Kura Oncology(KURA) shares are trading with a volume of 2.72M, against a daily average of 2.66M.
In the last year, Kura Oncology(KURA) shares hit a 52-week high of $16.68 and a 52-week low of $5.41.
In the last year, Kura Oncology(KURA) shares hit a 52-week high of $16.68 and a 52-week low of $5.41.
KURA News
On Thursday, the U.S. Food and Drug Administration granted full approval to Komzifti (ziftomenib), developed by Kura Oncology Inc. (NASDAQ:KURA) and Kyowa Kirin...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...